Vemurafenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Erdheim-Chester Disease ZELBORAF ® is indicated for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
Product first approved 2011Outside this platform's coverageFDA label
JP
  • Treatment of unresectable malignant melanoma with BRAF mutation
Product first approved 2014PMDA
EU
  • Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Product first approved 2012EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Melanoma
NCT01667419 · Hoffmann-La Roche
2012-09-24 – 2018-07-13 · Melanoma
What this study did
NCT02427893 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2015-08 – 2016-11 · Melanoma
What this study did
NCT01307397 · Hoffmann-La Roche
2011-03-01 – 2016-02-24 · Malignant Melanoma
What this study did
Other / comorbidity
NCT03768063 · Hoffmann-La Roche
2019-02-28 – 2028-07-05 · Cancer
What this study did
NCT06008119 · Shanghai Kechow Pharma, Inc.
2023-10-25 – 2026-12-24 · Colorectal Cancer Metastatic
What this study did
Phase 2/3 (3)
Melanoma
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
Phase 2 (69)
Melanoma
NCT04722575 · Fondazione Melanoma Onlus
2020-12-03 – 2027-06 · Melanoma
What this study did
NCT01659151 · H. Lee Moffitt Cancer Center and Research Institute
2012-08-03 – 2025-08-19 · Metastatic Melanoma
What this study did
NCT03554083 · Mayo Clinic
2018-10-05 – 2025-04-30 · Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
What this study did
NCT05263453 · Shanghai Kechow Pharma, Inc.
2021-09-06 – 2024-12-31 · Melanoma
What this study did
NCT02036086 · Sunnybrook Health Sciences Centre
2015-08 – 2024-01-31 · Melanoma
What this study did
NCT02968303 · Radboud University Medical Center
2017-01-27 – 2023-10 · Melanoma, Malignant, of Soft Parts
What this study did
NCT03430947 · Technische Universität Dresden
2018-07-01 – 2023-02-10 · Malignant Melanoma Stage IV, BRAF V600 Mutation, Brain Metastases
What this study did
NCT03224208 · Fondazione Melanoma Onlus
2018-05-17 – 2021-01-08 · Melanoma, Melanoma (Skin), Melanoma Stage
What this study did
NCT02414750 · Netherlands Working Group on Immunotherapy of Oncology
2014-12 – 2020-11 · Metastatic Melanoma
What this study did
NCT02303951 · University Hospital Tuebingen
2015-01-22 – 2020-05-14 · Malignant Melanoma
What this study did
NCT02537600 · Center Eugene Marquis
2015-12 – 2019-11-06 · Malignant Melanoma
What this study did
NCT03005639 · Inova Health Care Services
2017-06-01 – 2018-02-24 · Stage IIIB-C Melanoma
What this study did
NCT01813214 · Georgetown University
2013-03 – 2016-12 · Melanoma
What this study did
NCT01754376 · Massachusetts General Hospital
2013-01 – 2016-03 · Melanoma
What this study did
NCT02230306 · Melissa Burgess, MD
2015-02 – 2016-03 · Active Melanoma Brain Metastases
What this study did
NCT01942993 · Philip Friedlander
2013-09 – 2015-11 · Melanoma
What this study did
NCT01983124 · Paola Queirolo
2013-02 – 2015-09 · Malignant Melanoma Stage IV
What this study did
NCT02050321 · University of Arizona
2013-12 – 2015-07 · Malignant Melanoma
What this study did
NCT01378975 · Hoffmann-La Roche
2011-07 – 2015-07 · Malignant Melanoma
What this study did
NCT01673854 · Bristol-Myers Squibb
2012-09-13 – 2015-05-12 · Melanoma
What this study did
NCT02052193 · University Hospital Tuebingen
2014-01 – 2014-12-15 · Metastatic Melanoma (Carrying BRAF V600 Mutation)
What this study did
NCT00949702 · Hoffmann-La Roche
2009-09-30 – 2014-06-03 · Malignant Melanoma
What this study did
NCT01781026 · Yale University
2013-04 – 2014-06 · Melanoma
What this study did
NCT01474551 · Memorial Sloan Kettering Cancer Center
2011-11 – 2013-03 · Melanoma
What this study did
NCT01253564 · Hoffmann-La Roche
2010-11-22 – 2012-03-14 · Malignant Melanoma
What this study did
NCT01248936 · Hoffmann-La Roche
2010-12 – 2011-10 · Malignant Melanoma
What this study did
Other / comorbidity
NCT05159245 · Helsinki University Central Hospital
2021-12-10 – 2032-11-25 · Advanced Cancer, Solid Tumor, Haematological Malignancy
What this study did
NCT04302025 · Genentech, Inc.
2020-11-06 – 2030-05-30 · Non-small Cell Lung Cancer
What this study did
NCT04341181 · Ulrik Lassen
2020-08-24 – 2030-04-30 · Cancer, Tumors, Neoplasms, Neoplasia
What this study did
NCT06692491 · Peking University Shenzhen Hospital
2025-01-01 – 2029-12-31 · Rare Tumour
What this study did
NCT02693535 · American Society of Clinical Oncology
2016-03-14 – 2028-12-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT01709292 · M.D. Anderson Cancer Center
2012-11-07 – 2028-09-30 · Thyroid Cancer
What this study did
NCT03224767 · Alliance for Clinical Trials in Oncology
2018-01-05 – 2028-08-01 · BRAF V600E Mutation Present, Papillary Craniopharyngioma
What this study did
NCT04423185 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2020-08-15 – 2028-07-01 · Rare Tumor
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT02304809 · UNICANCER
2014-10-13 – 2027-10-13 · Solid Tumors, Hematologic Cancers, Metastatic Cancers
What this study did
NCT06561360 · Memorial Sloan Kettering Cancer Center
2024-09-09 – 2027-09-09 · Hairy Cell Leukemia
What this study did
NCT03181100 · M.D. Anderson Cancer Center
2017-07-27 – 2027-07-31 · Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma
What this study did
NCT04943198 · Anna Raciborska
2021-04-01 – 2027-06-30 · Histiocytosis
What this study did
NCT03297606 · Canadian Cancer Trials Group
2018-03-23 – 2027-01-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT03155620 · National Cancer Institute (NCI)
2017-07-31 – 2027-01-06 · Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
What this study did
NCT03410875 · Memorial Sloan Kettering Cancer Center
2018-02-09 – 2027-01 · Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell
What this study did
NCT06440850 · City of Hope Medical Center
2024-07-15 – 2026-11-22 · Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
What this study did
NCT05388123 · Scripps Health
2022-03-02 – 2026-04-01 · Hairy Cell Leukemia
What this study did
Phase 1/2 (8)
Melanoma
NCT01638676 · University of Louisville
2012-07 – 2027-06 · Melanoma
What this study did
NCT03101254 · Dana-Farber Cancer Institute
2017-06-06 – 2020-11-11 · Melanoma
What this study did
NCT02354690 · Inge Marie Svane
2014-11 – 2018-12-31 · Metastatic Melanoma
What this study did
NCT01959633 · Fondazione Melanoma Onlus
2014-04-03 – 2018-03-26 · Melanoma
What this study did
NCT01512251 · University of California, San Francisco
2012-06-09 – 2017-03-21 · BRAF Mutant Metastatic Melanoma
What this study did
Other / comorbidity
NCT04790448 · Sun Yat-sen University
2020-07-27 – 2021-12-31 · Colorectal Cancer Metastatic
What this study did
NCT03013491 · CytomX Therapeutics
2017-01-19 – 2020-10-27 · Solid Tumor, Lymphoma
What this study did
NCT02115035 · University of Arkansas
2014-07 – 2017-07 · Multiple Myeloma
What this study did
Phase 1 (50)
Melanoma
NCT02721459 · H. Lee Moffitt Cancer Center and Research Institute
2016-09-07 – 2026-11-04 · Melanoma, Skin Cancer
What this study did
NCT01843738 · University of Utah
2017-06 – 2022-08 · BRAFV600 Mutation, Stage IV Melanoma
What this study did
NCT01657591 · H. Lee Moffitt Cancer Center and Research Institute
2012-07-27 – 2021-09-21 · Melanoma
What this study did
NCT02818023 · Yana Najjar
2016-07-13 – 2021-04-23 · Melanoma
What this study did
NCT02145910 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
est. completion 2019-06 · Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
What this study did
NCT02608034 · Genentech, Inc.
2016-05-26 – 2018-09-10 · Metastatic Melanoma, BRAF V600 Mutation Positive
What this study did
NCT01876641 · Mohammed M Milhem
2013-10 – 2018-09 · Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
What this study did
NCT01910181 · Hoffmann-La Roche
2013-08-17 – 2018-04-20 · Malignant Melanoma
What this study did
NCT01271803 · Hoffmann-La Roche
2011-02-17 – 2017-12-12 · Malignant Melanoma
What this study did
NCT01603212 · M.D. Anderson Cancer Center
2013-07-18 – 2017-07-05 · Melanoma
What this study did
NCT02441465 · Hoffmann-La Roche
2015-08-13 – 2017-01-09 · Malignant Melanoma, Cancer
What this study did
NCT01943422 · John Kirkwood
2013-10 – 2016-12 · Melanoma
What this study did
NCT01897116 · Abramson Cancer Center at Penn Medicine
2013-06 – 2016-10-05 · Melanoma
What this study did
NCT01585415 · National Cancer Institute (NCI)
2012-04-09 – 2016-07-21 · Metastatic Cancer, Melanoma
What this study did
NCT01841463 · Piramal Enterprises Limited
2013-08 – 2016-03 · Advanced or Inoperable Malignant Melanoma With BRAF Mutation
What this study did
NCT00405587 · Plexxikon
2006-11 – 2016-02 · Malignant Melanoma, Colorectal Carcinoma
What this study did
NCT01519323 · Hoffmann-La Roche
2013-01 – 2015-12 · Malignant Melanoma
What this study did
NCT01765543 · Hoffmann-La Roche
2013-07 – 2015-11 · Malignant Melanoma, Neoplasms
What this study did
NCT02068079 · Duke University
2014-04 – 2015-11 · Melanoma
What this study did
NCT01826448 · Daiichi Sankyo
2013-11-05 – 2014-09-22 · V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma, Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
What this study did
NCT01835184 · National Cancer Institute (NCI)
2013-05 – 2014-09 · Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT02077114 · Herlev Hospital
2014-02 – 2014-09 · Malignant Melanoma With Metastasis
What this study did
NCT01844674 · Hoffmann-La Roche
2013-09-02 – 2014-08-26 · Malignant Melanoma, Neoplasms
What this study did
NCT01765569 · Hoffmann-La Roche
2013-07 – 2014-06 · Malignant Melanoma, Neoplasms
What this study did
NCT01851824 · Hoffmann-La Roche
2013-08 – 2014-06 · Malignant Melanoma, Neoplasms
What this study did
NCT01849666 · Hoffmann-La Roche
2013-09 – 2014-04 · Malignant Melanoma, Neoplasms
What this study did
NCT01611675 · Massachusetts General Hospital
2012-07 – 2014-01 · Melanoma
What this study did
NCT01400451 · Bristol-Myers Squibb
2011-11 – 2013-12 · Melanoma
What this study did
NCT01765556 · Hoffmann-La Roche
2013-10 – 2013-10 · Malignant Melanoma, Neoplasms
What this study did
NCT01107418 · Hoffmann-La Roche
2010-05 – 2013-02 · Malignant Melanoma
What this study did
NCT01164891 · Hoffmann-La Roche
2010-07 – 2012-12 · Malignant Melanoma
What this study did
NCT01001299 · Hoffmann-La Roche
2009-11-30 – 2012-02-29 · Malignant Melanoma
What this study did
Other / comorbidity
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT01748149 · University of California, San Francisco
2014-04-29 – 2025-07-31 · Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
What this study did
NCT02145143 · Memorial Sloan Kettering Cancer Center
2014-05-20 – 2024-11-21 · Thyroid Carcinoma
What this study did
NCT03781219 · Shanghai Kechow Pharma, Inc.
2018-07-01 – 2023-12-01 · Solid Tumor
What this study did
NCT04462471 · Memorial Sloan Kettering Cancer Center
2020-06-26 – 2023-09-29 · Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive
What this study did
NCT05019534 · West China Hospital
2021-08-15 – 2022-12-01 · BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
What this study did
NCT01787500 · M.D. Anderson Cancer Center
2013-02-15 – 2022-01-19 · BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
What this study did
NCT01531361 · M.D. Anderson Cancer Center
2012-02-06 – 2021-01-13 · Advanced Malignant Neoplasm, BRAF Gene Mutation, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01596140 · M.D. Anderson Cancer Center
2012-12-18 – 2020-06-01 · Advanced Cancer, Solid Tumor
What this study did
NCT01636622 · M.D. Anderson Cancer Center
2012-07-09 – 2020-04-21 · Advanced Cancers
What this study did
NCT02456701 · Celldex Therapeutics
2015-06 – 2016-10-13 · Thyroid Cancer
What this study did
NCT01791309 · Memorial Sloan Kettering Cancer Center
2013-01 – 2015-03 · Metastatic Colorectal Cancer
What this study did
NCT01974258 · Hoffmann-La Roche
2014-02 – 2014-07 · Neoplasms
What this study did
Phase 4 (4)
Melanoma
NCT01898585 · Hoffmann-La Roche
2013-10-17 – 2019-05-22 · Malignant Melanoma
What this study did
NCT01683188 · Clinigen, Inc.
2012-08 – 2014-11 · Metastatic Melanoma
What this study did
Other / comorbidity
Early phase / not applicable (3)
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT01636908 · Amsterdam UMC, location VUmc
2011-08 – 2019-12-01 · Cancer, Advanced Solid Tumors
What this study did
NCT03108209 · Michele Sayag
2016-07 – 2018-01 · Phototoxicity
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Melanoma
NCT01909453 · Pfizer
2013-09-12 – 2024-09-03 · Melanoma
What this study did
NCT01597908 · Novartis Pharmaceuticals
2012-06-04 – 2019-04-25 · Melanoma
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Melanoma
NCT01689519 · Hoffmann-La Roche
2013-01-08 – 2019-07-21 · Malignant Melanoma
What this study did
Phase 2 (1)
Melanoma
NCT01495988 · Melanoma Research Foundation Breakthrough Consortium
2013-08 – 2016-06 · Melanoma, Metastatic Melanoma
What this study did
Phase 1/2 (1)
Melanoma
NCT01616199 · Cascadian Therapeutics Inc.
2012-08 – 2015-03 · Advanced BRAF-mutant Cancers
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vemurafenib: this drugApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
ABM-1310
Discontinued
Small moleculeBRAF (V600 mutant)
not yet graded(overall)
No reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vemurafenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (2)
Phase 2Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary CarcinomaRecruiting
Est. primary completion 2026-11-22 · NCT06440850 · CT.gov ↗
What to watch
Phase 2Non-small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
December 2026 (2)
Phase 3Colorectal Cancer MetastaticRecruiting
Est. primary completion 2026-12-24 · NCT06008119 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
2027 (8)
January 2027 (1)
Phase 2Hairy Cell Leukemia, Leukemia, Leukemia, Hairy CellActive not recruiting
Est. primary completion 2027-01 · NCT03410875 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2HistiocytosisActive not recruiting
Est. primary completion 2027-06-30 · NCT04943198 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-07-31 · NCT03181100 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Hairy Cell LeukemiaRecruiting
Est. primary completion 2027-09-09 · NCT06561360 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Thyroid CancerActive not recruiting
Est. primary completion 2028-09-30 · NCT01709292 · CT.gov ↗
What to watch
2029 (4)
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2/3MelanomaRecruiting
Est. primary completion 2029-10 · NCT05768178 · CT.gov ↗
What to watch
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch

See the full readout calendar ↗